RxDoctor Payments Data

Bhuvaneswari Gowthaman, MD

Internal Medicine · Valencia, CANPI 1467435107

Payments from drug & device makers

$632in general payments, 2019–2025

Across 40 payments — averaging $15.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$135
  • Novo Nordisk$129
  • Boehringer Ingelheim$120
  • E.r. Squibb & Sons, L.L.C.$80
  • Amgen$64
  • Sobi, Inc$56
  • plus $48 from 3 others

What the payments were for

  • Food & beverage$61798%
  • Education$152%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$632 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$58,763
Medicare patients
152
Services billed
884

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide36$48,169
EliquisApixaban36$44,696
FarxigaDapagliflozin Propanediol34$40,151
JardianceEmpagliflozin16$24,689
JanuviaSitagliptin Phosphate13$20,199
MounjaroTirzepatide12$12,524
Incruse ElliptaUmeclidinium Bromide14$8,276
Atorvastatin Calcium476$4,571
Rosuvastatin Calcium290$4,325
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$4,067
Losartan Potassium243$2,861
Levothyroxine Sodium240$2,851
Wixela InhubFluticasone Propion/Salmeterol15$2,226
SynthroidLevothyroxine Sodium34$1,828
Amlodipine Besylate304$1,816

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$129$48,16936 claims
PfizerEliquis$135$44,69636 claims
AstraZenecaFarxiga$11$40,15134 claims
Boehringer IngelheimJardiance$120$24,68916 claims
MerckJanuvia$17$20,19913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Valencia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →